IldikoLingvayMDMPH, MSCS
Endocrinology • Dallas, TXDiabetes, Obesity, Thyroid
Professor of Internal Medicine/Endocrinology at University of Texas Southwestern Medical Center, Dallas, TX
Dr. Lingvay is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
5323 Harry Hines Blvd
Dallas, TX 75390Phone+1 214-645-2868Fax+1 214-648-8548
Summary
- Dr. Ildiko Lingvay is an endocrinologist in Dallas, TX and is affiliated with multiple hospitals in the area, including University of Texas Southwestern Medical Center, William P. Clements, Jr. University Hospital, and Parkland Health & Hospital System. She received her medical degree from Carol Davila University of Medicine and Pharmacy and has been in practice 19 years. She specializes in diabetes, lipid metabolism, and thyroid.
Education & Training
University of Texas Southwestern Medical CenterFellowship, Endocrinology, Diabetes, and Metabolism, 2002 - 2005
Texas Tech University (Permian Basin)Residency, Internal Medicine, 1999 - 2002
Carol Davila University of Medicine and PharmacyClass of 1998
Certifications & Licensure
TX State Medical License 2002 - 2025- American Board of Internal Medicine Endocrinology, Diabetes and Metabolism
- American Board of Obesity Medicine Obesity Medicine
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012
Clinical Trials
- Preservation of Beta-cell Function in Type 2 Diabetes Mellitus Start of enrollment: 2003 Nov 01
- Role of Pancreatic Triglyceride Content in Beta-cell Function Start of enrollment: 2007 Sep 01
- Changes in Ectopic Fat Following Surgically Induced Weight Loss Start of enrollment: 2008 Aug 01
- Join now to see all
Publications & Presentations
PubMed
- Glucagon-like Peptide-1 receptor agonists versus dipeptidyl-peptidase 4 inhibitors in advanced chronic kidney disease and end stage kidney disease: Real world effectiv...F N U Sidra, Shubham Agarwal, Paola Lockhart Pastor, Donglu Xie, Xilong Li
Journal of Diabetes and Its Complications. 2025-01-01 - Healthcare utilization, mortality, and cardiovascular events following GLP1-RA initiation in chronic kidney disease.Shuyao Zhang, Fnu Sidra, Carlos A Alvarez, Mustafa Kinaan, Ildiko Lingvay
Nature Communications. 2024-12-05 - Pharmacokinetic/Pharmacodynamic Modeling of Efficacy and Hypoglycemia Rate When Switching From Once-Daily Basal Insulin to Once-Weekly Insulin Icodec Without or With a...Ildiko Lingvay, Björg Ásbjörnsdóttir, Niels R Kristensen, Christian Laugesen, André Vianna
Endocrine Practice. 2024-12-02
Journal Articles
- Once-Weekly Semaglutide in Adults with Overweight or ObesityIldiko Lingvay, Barbara M Mcgowan, Julio Rosenstock, Marie TD Tran, Thomas A Wadden, The New England Journal of Medicine
- A 26-Week Randomized Controlled Trial of Semaglutide Once Daily Versus Liraglutide and Placebo in Patients with Type 2 Diabetes Suboptimally Controlled on Diet and Exe...Ildiko Lingvay, Cyrus V Desouza, Diabetes Care
Press Mentions
A Powerhouse of Obesity Research – Then and NowSeptember 20th, 2024- Type 1 Diabetes and Use of ‘Off-Label’ Drugs: Benefits, but Concerns, TooFebruary 20th, 2023
- Study Provides a Rare View of Real-World Use of off-Label Drugs Prescribed for Type 1 DiabetesFebruary 16th, 2023
- Join now to see all
Grant Support
- Role Of Pancreatic Triglycerides In Beta-Cell DysfunctionNational Center For Research Resources2007–2011
Other Languages
- Romanian, Hungarian
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
